GC Biopharma

(주)녹십자 · KOSPI · 006280 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩522.1bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+24.0% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY-14.3% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026₩49.2bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+2746.1% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+68.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩59.2bn As of Nov 2, 2026 Source 1
Supply contracts vs prior-year revenue3.0% As of Nov 2, 2026 Source 1
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months4 As of Nov 19, 2026
DART filings, previous 3 months12 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)750 shares As of Jul 31, 2026 Source 1 ↗, Source 2 ↗
Open-market buys, last 12 months (amount)₩89m As of Jul 31, 2026 Source 1 ↗, Source 2 ↗
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)750 shares As of Jul 31, 2026 Source 1 ↗, Source 2 ↗
Insiders who bought, last 12 months2 As of Jul 31, 2026 Source 1 ↗, Source 2 ↗

Insider transactions (last 12 months)

Open-market buys: 750 shares (₩89m). Open-market sells: 0 shares (₩0). Net open-market buying: +750 shares. Insiders who bought: 2.

Trade dateInsider (role)TypeSharesPriceAmount
Jul 31, 2026Choi Yeong-il (Non-registered officer)Open-market buy+500 shares₩117,800₩59m
Jun 15, 2026Jung Jae-uk (Registered director)Open-market buy+250 shares₩121,348₩30m
Jan 1, 2026Son Seok-u (Non-registered officer)Other (New report)+25 shares——

Annual financials

YearRevenueOperating income
2025₩2.0tn₩69.1bn
2024₩1.7tn₩32.1bn
2023₩1.6tn₩34.4bn

Filing timeline